Just a few weeks after earning a permanent injunction barring the use of Invitae’s Personalized Cancer Monitoring tests, Natera is taking another of the diagnostic developer’s product portfolios off ...

Dublin, Dec. 10, 2019 (GLOBE NEWSWIRE) -- The "Carrier Screening Market by Product and Service, Type (Expanded Carrier (Predesigned, Customized), Targeted Disease Carrier), Medical Condition ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

Invitae (NYSE: NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test for hereditary cancer risk. The U.S. Food and Drug ...